Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Core Insights - Zelluna has announced a clinical partnership with Medpace to support the first clinical trial of its lead product candidate, ZI-MA4-1, which is an allogeneic T Cell Receptor-based Natural Killer (TCR-NK) cell therapy for solid cancers [1][3][10] Company Overview - Zelluna ASA is pioneering TCR-NK cell therapies targeting solid cancers, with ZI-MA4-1 being the world's first MAGE-A4 targeting TCR-NK therapy [7] - The company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker ZLNA [7] Clinical Development - The partnership with Medpace is a strategic move for Zelluna as it transitions from preclinical to clinical stage, providing access to necessary infrastructure and expertise for executing complex cell therapy trials [3][6] - The planned Phase 1 study will assess safety, tolerability, and early signs of clinical activity in patients with advanced solid cancers, including lung cancer, ovarian cancer, head and neck cancer, and sarcomas [5][10] - Initial clinical data from the trial is expected to emerge from mid-2026, marking the first clinical validation of Zelluna's proprietary TCR-NK platform [5][10] Medpace's Role - Medpace will offer comprehensive clinical development services, including clinical operations, trial management, regulatory support, data management, and pharmacovigilance [3][10] - The collaboration is expected to enhance the efficiency and rigor of the clinical study, leveraging Medpace's deep oncology expertise and strong track record in early-phase development [6][10]